Developing a PTEN-ERG Signature to Improve Molecular Risk Stratification in Prostate Cancer
Technical Report,30 Sep 2016,29 Sep 2017
John Hopkins University Baltimore United States
Pagination or Media Count:
Based on previous work and our own preliminary data, it is clear that there exist distinctive molecular correlates of PTEN loss in the context of ETS-negative versus ETS-positive human prostate cancers and that these may drive prognosis following PTEN loss. Ultimately, elucidation of the molecular underpinnings of PTEN-ERG crosstalk holds promise for clarifying the mechanisms underlying the aggressive behavior seen in ERG-negativePTEN-negative tumors, and may enable rational design of more effective therapeutic strategies and prognosticators for this subset of patients. We propose to test two hypotheses generated by our preliminary data 1 PTEN loss in the absence of ETS gene expression is associated with an increased proliferative rate and a significantly increased risk of metastasis and death and 2 ETS expression interacts with PTEN loss to modulate the transcriptional output from key oncogenic transcription factors such as MYC. Here we report on the initial studies performed for this award.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology